A Study to Evaluate the Real-world Experience and Satisfaction Associated With Ofatumumab
A Study Investigating Drivers of Physician and Patient Satisfaction Towards Treatment
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Basel, Switzerland, CH-4056
- Novartis
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Physician inclusion criteria:
- Physicians must be actively involved in the treatment/management of patients with MS
- Consult with a minimum of 16 MS patients (>5 in Japan and China, >10 in Brazil) per month
Patient inclusion criteria:
Patients for whom physicians complete a Physician Completed Patient Record Form (PRF), and therefore are included in the pool of data for analysis, are based on the following criteria:
- Patients who had a physician-made diagnosis of MS before or at the time of data collection
- Patients must not currently be involved in a clinical trial
- Patients ≥18 years old
- For patients included in the ofatumumab sample, they must have been receiving ofatumumab for >12 months at the time of data collection
Exclusion criteria:
• None
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
MS Patient Cohort
Adult patients diagnosed with relapsing multiple sclerosis (RMS) who received treatment with ofatumumab, and were invited to participate following a consult with their physician.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number and Percentage of Patients by Patient-reported Level of Satisfaction With Current MS Treatment
Time Frame: 1 Day
|
Patient's level of satisfaction with current treatment categorized as follows:
|
1 Day
|
|
Number and Percentage of Patients by Patient-reported MS Status With Their Current Medication Compared to Previous Medication
Time Frame: 1 Day
|
MS status, as reported by the patient, categorized as follows:
|
1 Day
|
|
Number and Percentage of Patients by Physician-reported Patient Response to Current MS Treatment
Time Frame: 1 Day
|
How well the patient is responding to current treatment rated by the physician from 1 (very poorly) to 5 (very well).
|
1 Day
|
|
Number and Percentage of Patients by Physician-reported Level of Satisfaction With the Patient's Current MS Treatment
Time Frame: 1 Day
|
Physician's level of satisfaction with patient's current treatment categorized as follows:
|
1 Day
|
|
Number and Percentage of Patients Adherent to Current MS Treatment as Reported by the Physician
Time Frame: 1 Day
|
Adherence, as reported by the physician, categorized as follows:
|
1 Day
|
|
Number and Percentage of Patients by Physician-reported Change in Patient Condition Since Initiation of Current MS Treatment
Time Frame: 1 Day
|
Change in condition, as reported by the physician, categorized as follows:
|
1 Day
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number and Percentage of Patients by Factors That Influence How the Patient Rates Current Medication Compared to Previous Medication
Time Frame: 1 Day
|
Factors influencing how patients rate medication include:
|
1 Day
|
|
Number and Percentage of Patients by Physician-reported Reason for Current MS Treatment Choice
Time Frame: 1 Day
|
1 Day
|
|
|
Number and Percentage of Patients by Physician-reported Top 5 Reasons for Current MS Treatment Choice
Time Frame: 1 Day
|
1 Day
|
|
|
Number and Percentage of Patients by Physician-reported Main Areas of Improvement for the Patient's Current MS Treatment
Time Frame: 1 Day
|
1 Day
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- COMB157G2021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.